Vir Biotechnology amends bylaws with enhanced stockholder nomination requirements and procedural updates

Vir Biotechnology, Inc.

Eliminated requirement to make stockholder list available at meeting; added adjournment for technical failure.
Enhanced disclosure requirements for stockholder nominations and proposals, including Rule 14a-19 compliance.
Non-compliance with Rule 14a-19 may result in disregarding nominees and votes.
Added emergency bylaw provision for director and officer authority during crises.
Other technical, conforming, and clarifying changes made to reflect Delaware law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Vir Biotechnology, Inc.: Amended and restated bylaws to reflect recent legal changes, procedural updates, and enhance stockholder proposal and director nomination requirements (effective 2023-03-02).

Change: bylaw amendment
Effective: 2023-03-02

Exact text from the filing

On March 2, 2023, the Board of Directors of Vir Biotechnology, Inc. (the “Company”) unanimously adopted amended and restated bylaws of the Company (as so amended and restated, the “Bylaws”). The Bylaws, which became effective upon adoption, make modifications to reflect recent changes to applicable laws as well as certain procedural and other updates.

View on SEC.gov

27 governance changes filed in the last 30 days. Browse all governance changes →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-064485

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.